Search

Displaying results 5581 - 5590 of 10000 in total
  1. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.

  2. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  3. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.

  4. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Prasterone sulfate

    go.drugbank.com/drugs/DB05804
    Investigational

    DHEA sulfate is the major steroid of the fetal adrenal. DHEA-S is the principal adrenal androgen and is secreted together with cortisol under the control of ACTH and prolactin. DHEA-S is elevated with hyperprolactinemia.

    Categories: Cytochrome P-450 CYP3A7 Substrates
  6. Drug

    Cefacetrile

    go.drugbank.com/drugs/DB01414
    InvestigationalVet approved

    A derivative of 7-aminocephalosporanic acid.

  7. Drug

    Melanoma antigen recognized by T-cells 1

    go.drugbank.com/drugs/DB15081
    Investigational

    Melanoma antigen recognized by T-cells 1 is under investigation in clinical trial NCT01748747 (Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

    Synonyms: ANTIGEN LB39-AA, ANTIGEN SK29-AA
  8. Drug

    PF-08046040

    go.drugbank.com/drugs/DB17555
    Investigational

    SEA-CD70 is an investigational humanized, non-fucosylated monoclonal antibody targeting CD70. … SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).

  9. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. … Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

  10. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential